Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide in Early Parkinson's Disease
NCT03439943Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2018
- Primary completion
- Apr 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Lixisenatide with Placebo (2 arms). Primary endpoint: Movement Disorder Society-Unified Parkinson's disease rating scale Part III motor score at 12 months. Started Jun 2018; status: completed.
02
Drugs
lixisenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03439943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439943.